A modern approach to CAR-T cell therapy, engineered directly in vivo—within the patient’s body—is showing promising early results in treating multiple myeloma, a cancer of plasma cells. This innovative method bypasses the complex and costly process of extracting, modifying, and re-infusing a patient’s T cells, potentially making this powerful immunotherapy more accessible and faster to deploy. Initial clinical data, published in Nature Medicine on March 25, 2026, reveals key insights into how this “self-engineered” therapy functions and its potential to reshape cancer treatment.
For years, CAR-T cell therapy—chimeric antigen receptor T-cell therapy—has offered hope to patients with certain blood cancers. However, the standard process is intricate. Doctors collect a patient’s T cells, genetically engineer them to express a receptor (the CAR) that recognizes a specific protein on cancer cells, and then grow these modified cells in a lab before infusing them back into the patient. This process, while effective, is expensive, time-consuming, and can have significant side effects. The new in vivo approach aims to simplify this process, offering a potential solution to these challenges. This emerging field of in vivo CAR-T cell therapy represents a significant shift in how we approach immunotherapy.
The research team, led by scientists at the University of Pennsylvania, developed a viral vector—essentially a harmless delivery vehicle—that carries the genetic instructions for creating the CAR directly into the patient’s body. This vector specifically targets T cells, delivering the CAR gene and prompting the cells to begin expressing the cancer-targeting receptor without the need for external manipulation. The initial clinical trial involved a small cohort of patients with relapsed or refractory multiple myeloma, meaning their cancer had returned or stopped responding to other treatments. According to the study, the in vivo CAR-T cells demonstrated encouraging anti-tumor activity, with several patients experiencing a reduction in their cancer burden.
How In Vivo Engineering Works: A Targeted Approach
The key to this in vivo engineering lies in the specificity of the viral vector. Researchers carefully designed the vector to target T cells within the patient’s body, minimizing off-target effects. The vector delivers the genetic code for a CAR that recognizes BCMA (B-cell maturation antigen), a protein found on the surface of multiple myeloma cells. Once inside the T cells, this genetic code instructs the cells to produce the CAR receptor. These newly equipped T cells then circulate throughout the body, seeking out and destroying myeloma cells. This differs significantly from traditional CAR-T therapy, which requires the cells to be modified outside the body and then reintroduced.
The study also shed light on the dynamics of these in vivo engineered CAR-T cells. Researchers observed that the CAR expression levels were lower compared to those achieved with traditional CAR-T therapy. However, the in vivo CAR-T cells demonstrated sustained activity over a longer period, potentially due to a more natural integration of the CAR gene into the T cell genome. This sustained activity is a crucial factor in achieving long-term remission, and further research is underway to optimize CAR expression levels. Understanding the persistence and functionality of these cells is critical for maximizing therapeutic benefit.
Early Clinical Trial Results and Patient Impact
The phase 1 clinical trial, conducted at the University of Pennsylvania’s Perelman School of Medicine, enrolled 12 patients with advanced multiple myeloma. The trial primarily aimed to assess the safety and feasibility of the in vivo CAR-T cell therapy. Preliminary results showed that the therapy was generally well-tolerated, with manageable side effects. While cytokine release syndrome (CRS), a common side effect of CAR-T therapy, was observed in some patients, it was typically mild to moderate and responsive to treatment. The National Cancer Institute provides detailed information about cytokine release syndrome.
More importantly, the trial demonstrated evidence of anti-tumor activity. Five patients experienced a partial response, meaning their cancer shrank, and two patients achieved very good partial response, indicating a significant reduction in their disease burden. Researchers are continuing to monitor these patients to assess the durability of these responses. The study also revealed that the in vivo CAR-T cells were able to effectively target and kill myeloma cells in the bone marrow, where the cancer often resides. This targeted approach minimizes damage to healthy cells, potentially reducing side effects.
Streamlining Immunotherapy: Accessibility and Future Directions
One of the most significant advantages of in vivo CAR-T cell therapy is its potential to streamline the manufacturing process and reduce costs. Traditional CAR-T therapy requires specialized facilities and highly trained personnel to collect, modify, and grow T cells. This complex process can capture weeks and cost hundreds of thousands of dollars per patient. The in vivo approach eliminates these steps, potentially making CAR-T therapy more accessible to a wider range of patients. This is particularly important for patients in rural areas or those with limited access to specialized cancer centers.
Researchers are now focused on optimizing the viral vector to enhance CAR expression levels and improve the efficacy of the therapy. They are also exploring the potential of combining in vivo CAR-T cell therapy with other cancer treatments, such as chemotherapy and immunotherapy. Future clinical trials will involve larger patient cohorts and will evaluate the therapy in other types of cancer. The team is also investigating ways to personalize the therapy by tailoring the CAR to each patient’s specific cancer cells. The next phase of clinical trials is expected to begin in late 2026, focusing on expanding the patient population and refining the treatment protocol.
The development of in vivo CAR-T cell therapy represents a significant step forward in the field of immunotherapy. While still in its early stages, this innovative approach holds the promise of making this life-saving treatment more accessible, affordable, and effective for patients with cancer. Further research and clinical trials are needed to fully realize its potential, but the initial results are encouraging and suggest a bright future for this groundbreaking technology.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts on this exciting development in cancer treatment in the comments below. We encourage you to share this article with anyone who might benefit from this information.
Worth a look
